Impact of the Delta variant on vaccine efficacy and response strategies.
Lianlian Bian,Qiushuang Gao,Fan Gao,Qian Wang,Qian He,Xing Wu,Qunying Mao,Miao Xu,Zhenglun Liang +8 more
Reads0
Chats0
TLDR
In this paper, the authors reviewed the evolution of the Delta variant of SARS-CoV-2, including the Delta Plus variant with a K417N mutation in the RBD, which may confer an improved immune evasion ability.Abstract:
Introduction The Delta variant of SARS-CoV-2 has caused a new wave of the COVID-19 epidemic in many countries. It is the most infectious variant of SARS-CoV-2 to date, and its high infectivity means that a higher proportion of the population needs to be vaccinated to reduce the disease burden, which poses a substantial public health challenge. Areas covered The evolution of the Delta variant is reviewed, including an overview of the Delta Plus variant with a K417N mutation in the RBD, which may confer an improved immune evasion ability. Decreases in serum neutralizing antibody titers after vaccination against Delta were greater than those against Alpha but less than those against Beta. The protective efficacy of existing vaccines against the Delta variant have declined and is related to the number of doses and the time since vaccination. Expert opinion The currently used vaccines are effective against hospitalization/severe disease due to the Delta variant. Accelerating the popularization of vaccination, improving the coverage rate, and the implementation of intervention measures, such as wearing masks, are effective means to control the spread of the Delta variant and other variants. However, vaccination alone against SARS-CoV-2 without intervention measures may lead to continuous spread and the emergence of new variants.read more
Citations
More filters
Journal ArticleDOI
The Lancet Commission on lessons for the future from the COVID-19 pandemic
TL;DR: The COVID-19 Commission report as mentioned in this paper provides a conceptual framework for understanding pandemics and proposes guideposts for strengthening the multilateral system to address global emergencies and to achieve sustainable development.
Journal ArticleDOI
The Lancet Commission on lessons for the future from the COVID-19 pandemic
Jeffrey D. Sachs,Salim S. Abdool Karim,Lara B. Aknin,J. Allen,Kirsten Brosbøl,Francesca Colombo,Gabriela Cuevas Barron,María Fernanda Espinosa,Vitor Gaspar,Alejandro Gaviria,Andy Haines,Peter J. Hotez,Phoebe Koundouri,Felipe Larraín Bascuñán,Jong Koo Lee,Muhammad Pate,Gabriela Ramos,K.S. Reddy,Ismail Serageldin,John Thwaites,Vaira Vike-Freiberga,Chen Wang,Miriam Were,Lan Xue,Chandrika Bahadur,Maria Elena Bottazzi,Chris Bullen,George Laryea-Adjei,Yanis Ben Amor,O. Karadag,Guillaume Lafortune,Emma Torres,Lauren Barredo,Juliana G E Bartels,Neena Joshi,Margaret Hellard,Uyen Kim Huynh,Shweta Khandelwal,Jeffrey V. Lazarus,Susan Michie +39 more
TL;DR: The winners will be announced at a special ceremony in New York later this month.
Journal ArticleDOI
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines
Suresh Thakur,Shalitha Sasi,Sindhu Gopinathan Pillai,Ayantika Nag,Dhananjay Shukla,Ritu Singhal,Sameer Phalke,Geetha Velu +7 more
TL;DR: The mutational landscape on the SARS-CoV-2 structural and non-structural proteins and their impact on diagnostics, therapeutics and vaccines are reviewed and the effectiveness of approved vaccines, antibody therapy and convalescent plasma on the currently prevalent VOCs are looked at.
Journal ArticleDOI
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Daniel W. Kneller,Hui Li,Gwyndalyn Phillips,Kevin L. Weiss,Qiu-Fen Zhang,Mark A. Arnould,Colleen B. Jonsson,Surekha Surendranathan,Jyothi Parvathareddy,Matthew P. Blakeley,Leighton Coates,John M. Louis,Peter V. Bonnesen,Andrey Kovalevsky +13 more
TL;DR: In this paper , the authors performed the design and characterization of three covalent hybrid inhibitors for SARS-CoV-2 and NBH-2, which were created by splicing components of hepatitis C protease inhibitors boceprevir and narlaprevir and showed that a Cys145 thiolate reaction with the inhibitor's ketowarhead creates a negatively charged oxyanion.
Journal ArticleDOI
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jianguo Jin,Chengcheng Li,Chunhong Ye,Zhihui Ruan,Yicong Liang,Yongkui Li,Jianguo Wu,Zhen Luo +7 more
TL;DR: Wang et al. as discussed by the authors systematically summarized two main therapeutic strategies against the coronavirus disease 2019 (COVID-19) pandemic, namely drugs targeting the SARS-CoV-2 life cycle, and drugs targeting SARS CoV2 induced inflammation in host cells.
References
More filters
Journal ArticleDOI
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.
Qun Li,Xuhua Guan,Peng Wu,Xiaoye Wang,Lei Zhou,Yeqing Tong,Ruiqi Ren,Kathy Leung,Eric H. Y. Lau,Jessica Y. Wong,Xuesen Xing,Nijuan Xiang,Yang Wu,Chao Li,Chen Qi,Dan Li,Tian Liu,Jing Zhao,Man Liu,Wenxiao Tu,Chuding Chen,Lianmei Jin,Rui Yang,Qi Wang,Suhua Zhou,Rui Wang,Hui Liu,Yingbo Luo,Yuan Liu,Ge Shao,Huan Li,Zhongfa Tao,Yang Yang,Yang Yang,Zhiqiang Deng,Boxi Liu,Zhitao Ma,Yanping Zhang,Guoqing Shi,Tommy Tsan-Yuk Lam,Joseph T. Wu,George F. Gao,George F. Gao,Benjamin J. Cowling,Bo Yang,Gabriel M. Leung,Zijian Feng +46 more
TL;DR: There is evidence that human-to-human transmission has occurred among close contacts since the middle of December 2019 and considerable efforts to reduce transmission will be required to control outbreaks if similar dynamics apply elsewhere.
Journal ArticleDOI
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Jun Lan,Jiwan Ge,Jinfang Yu,Sisi Shan,Huan Zhou,Shilong Fan,Qi Zhang,Xuanling Shi,Qisheng Wang,Linqi Zhang,Xinquan Wang +10 more
TL;DR: High-resolution crystal structures of the receptor-binding domain of the spike protein of SARS-CoV-2 and SARS -CoV in complex with ACE2 provide insights into the binding mode of these coronaviruses and highlight essential ACE2-interacting residues.
Journal ArticleDOI
Cell entry mechanisms of SARS-CoV-2.
TL;DR: Key cell entry mechanisms of SARS-CoV-2 that potentially contribute to the immune evasion, cell infectivity, and wide spread of the virus are identified using biochemical and pseudovirus entry assays and the potency and evasiveness are highlighted.
Journal ArticleDOI
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Delphine Planas,David Veyer,Artem Baidaliuk,Isabelle Staropoli,Florence Guivel-Benhassine,Maaran Michael Rajah,Maaran Michael Rajah,Cyril Planchais,Françoise Porrot,Nicolas Robillard,Julien Puech,Matthieu Prot,Floriane Gallais,Pierre Gantner,Aurélie Velay,Julien Le Guen,Najiby Kassis-Chikhani,Dhiaeddine Edriss,Laurent Bélec,Aymeric Sève,Laura Courtellemont,Hélène Péré,Laurent Hocqueloux,Samira Fafi-Kremer,Thierry Prazuck,Hugo Mouquet,Timothée Bruel,Etienne Simon-Loriere,Félix A. Rey,Olivier Schwartz +29 more
TL;DR: In this paper, an infectious strain of the SARS-CoV-2 Delta variant was isolated from an individual with COVID-19 who had returned to France from India.
Journal ArticleDOI
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Eric J. Haas,Eric J. Haas,Frederick J. Angulo,John M McLaughlin,Emilia Anis,Emilia Anis,Shepherd Roee Singer,Shepherd Roee Singer,Farid Khan,Nati Brooks,Meir Smaja,Gabriel Mircus,Kaijie Pan,Jo Southern,David L. Swerdlow,Luis Jodar,Yeheskel Levy,Sharon Alroy-Preis +17 more
TL;DR: In this article, the real-world effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide public-health impact following the widespread introduction of the vaccine was estimated.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more